CGTX Stock Analysis: Buy, Sell, or Hold?
CGTX - Cognition Therapeutics, Inc. Common Stock
$1.00
0.04 (4.10%)
â˛
5d:
-1.4%
30d:
+3.72%
90d:
-20.33%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When CGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CGTX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CGTX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CGTX is currently trading at $1.00, which is considered fair relative to its 30-day fair value range of $0.92 to $1.04.
Technical Outlook: Technically, CGTX is in a strong uptrend. Immediate support is located at $0.93, while resistance sits at $1.10. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: CGTX scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.33 (+234.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CGTX is in a strong uptrend. Immediate support is located at $0.93, while resistance sits at $1.10. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: CGTX scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.33 (+234.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.92 -
$1.04
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.1%)
- BULLISH: Trading 234.7% below Wall St target ($3.33)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.92 -
$1.04
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.93
Resistance Level
$1.10
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.53
Wall Street Target
$3.33
(+234.7%)
Share & Embed Analysis
Last updated: August 22, 2026 10:26 PM ET
Data refreshes hourly during market hours. Next update: 11:26 PM
Data refreshes hourly during market hours. Next update: 11:26 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGTX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
John Brendan Doyle
BUY
10000 shares
2026-04-16
Lisa Ricciardi
BUY
9175 shares
2026-04-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$834 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$39 | 52 HOLD |
